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late onset Alzheimer's disease (LOAD). The PMBCswere reprogrammedwith the humanOSKM transcription fac-
tors using the Sendai-virus delivery system. The transgene-free iPSC showed pluripotency veriﬁed by immuno-
cytochemistry for pluripotency markers and differentiated spontaneously towards the 3 germ layers in vitro.
Furthermore, the iPSC line showed normal karyotype. Our model might offer a good platform to further study
the pathomechanism of sporadic AD, to identify early biomarkers and also for drug testing and gene therapy
studies.
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To generate the BIOT-0630-LOAD iPSC line (Fig. 1A) the four
“Yamanaka reprogramming factors” OCT3/4, SOX2, KLF4, and C-MYC
were delivered into PBMCs using the integration-free Sendai virus
gene-delivery method (Yang et al. 2008; Fusaki et al. 2009). The
iPSC-like colonies were picked after 20–27 days post-transduction.
Beginning from passage 5 of the iPSCs the absence/presence of Sendai
virus vector was analysed by RT-PCR using Sendai virus vector (SeV) -
speciﬁc primers (Table 1). After 7 passages, the elimination of the
reprogramming vector was conﬁrmed in BIOT-0630-LOAD iPSC line
which was selected for further analysis (Fig. 1B).
The karyotype of the BIOT-0630-LOAD iPSC line was determined
with Giemsa-banding, proving normal diploid 46, XY karyotype, with-
out any detectable abnormalities (Fig. 1B).
Expression of pluripotency markers was examined by immuno-
cytochemistry staining, using antibodies against human OCT3/4,
E-CADHERIN, and NANOG (Fig. 1A). The in vitro spontaneous differen-
tiation potential towards the three germ layer of the BIOT-0630-LOAD
iPSC line was demonstrated by the expression of ectodermal (βIII-TU-
BULIN), mesodermal (BRACHYURY) and endodermal (GATA4) markers
(Fig. 1A) (Itskovitz-Eldor et al. 2000; Carpenter et al. 2003).Materials and methods
Reprogramming of peripheral blood mononuclear cells (PBMC)
PBMCs were isolated within 2 h post-collection using the
Vacutainer® CPT™ Cell Preparation Tube with Sodium Heparin, (BDthe CC BY license (http://creativecommons.org/licenses/by/4.0/).
Fig. 1.Characterisation of BIOT-0630-LOADhiPSC line A) Above:Morphology of generated hiPSCs (4×) and representative immunoﬂuorescentmicrographs of iPSCs positive for stem cells
markers OCT3/4, NANOG and E-CADHERIN (in green). Alkaline phosphatase (AP) activity was also detected in iPSCs. Below: Spontaneously formed EBs in suspension culture (Day 5) and
after attachment and further differentiation (Day 14). Immunostainings for endodermal (GATA4), mesodermal (BRACHYURY) and ectodermal (βIII-TUBULIN) germ layers, markers (in
green). Nucleus is labelled with DAPI (in blue). B) RT-PCR veriﬁcation of the absence of Sendai-virus from the reprogrammed cells and karyogram showing normal 46 chromosomes (XY).
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temperature (RT). The freshly isolated PBMCs were seeded (0.5 × 106
cells) in Expansion Medium (EM): QBSF-60 medium (Quality Biolog-
ical) supplemented with 50 μg/ml Ascorbic acid, 1% Penicillin/Strep-
tomycin, 50 ng/ml SCF (R&D systems), 10 ng/ml IL-3 (R&D systems),
2 U/ml EPO (R&D systems), 40 ng/ml IGF-1 (R&D systems) and 1 μM
Dexamethasone. Nine days later (Day 0) the cells were transduced
by Sendai-virus delivery using the CytoTune®-iPS 2.0 Sendai
Reprogramming Kit (Thermo Fisher Scientiﬁc), following the
manufacturer's instruction. Brieﬂy, the cells were transduced on
1w/24wp in 1 ml EM supplemented with 4 μg polybrene. The calculat-
ed volumes of each of the three CytoTune™ 2.0 Sendai-virus (SeV) was
added to the cells using MOI of 5-5-3 (KOS MOI = 5, hc-Myc MOI = 5,
hKlf4 MOI = 3). The cell containing plate was centrifuged (900 rcf,
90min, RT) and incubated for 24 h. The following day the cellswere col-
lected, centrifuged (300 rcf, 5 min, RT) and seeded in fresh EM (Day 1).
Two days later (Day 3) the cells were passed onto a 6 cm dish covered
with 0.1% gelatine and 0.65 × 106 Mitomycin C treated-MEF in QBSF-
60 medium (Quality Biological) supplemented with 50 μg/ml Ascorbic
acid. Seven days post-transduction (Day 7) the medium was
replaced with HESC medium: DMEM/F12, 20% Knockout Serum
Replacement, 1% MEM Non-Essential Amino Acid Solution, 0.1 mMTable 1
Primers used in the study.
Gene symbol Fwd and Rvs primers (5′-3′) PCR product (bp)
SeV GGATCACTAGGTGATATCGAGC
ACCAGACAAGAGTTTAAGAGATATGTATC
181
RPS18S TTAAGGGTGTGGGCCGAAGA
GGGATCTTGTACTGGCGTGGA
142β-mercaptoethanol, 0.5% Pen/Strep, 10 ng/ml bFGF and supplemented
with 50 μg/ml Ascorbic acid. The colonies with an ES-like appearance
were manually isolated based on morphology between Day 21 to Day
27 post-transduction and cultured as iPSCs thereafter. Human iPSC
cultures were maintained on plates coated with Matrigel (BD Biosci-
ences) in mTESR-1 medium (Stem Cell Technologies) following the
manufacturer's instruction (Fig. 1A). All cells were cultured at 37 °C in
humidiﬁed atmosphere containing 5% CO2.Reverse transcription polymerase chain reaction (RT-PCR)
Total RNA was isolated from cultured cells with RNeasy Micro Kit
(Qiagen) and reverse transcribed corresponding to SuperScript III
Reverse Transcriptase protocol (Thermo Fisher Scientiﬁc). The RT-PCR
reaction was performed using GoTaq Hot Start Green Master Mix
(Promega). To conﬁrm the transgene-free status of the iPSC lines, SeV
speciﬁc primers were used described in CytoTune®-iPS 2.0 Sendai
Reprogramming Kit protocol (Thermo Fisher Scientiﬁc; Table 1).In vitro spontaneous differentiation
The iPSCs were harvested according to the mTeSR-1 kit protocol
(StemCell Technologies) and the cell clumpswere plated on lowattach-
ment dishes in mTeSR medium. Five days later the embryoid bodies
(EBs) that had formed were plated on 24-well plates containing cover
slips (3–4 EBs/well), covered with 0.1% gelatin in differentiation medi-
um: DMEM, 20% FBS, 1% MEM Non-Essential Amino Acid Solution,
0.1 mM β-mercaptoethanol, 1% Pen/Strep. The medium was changed
in every secondday hereafter. The cellswere ﬁxed on day 14 of differen-
tiation with 4% PFA for ICC staining speciﬁc for the 3 germ layers.
Table 2
Antibodies used for immunocytochemistry.
Antibody Dilution Company (Cat #)
Pluripotency Mouse anti-E-CADHERIN 1:1000 Thermo Fisher Scientiﬁc
(13-1700)
Mouse anti-OCT4 1:50 Santa Cruz
Biotechnologies
(sc-5279)
Goat anti-hNANOG 1:50 R&D (AF1997)
In vitro
differentiation
Rabbit anti-β-III-TUBULIN 1:2000 Covance (PRB-435P)
Rabbit anti-BRACHYURY T 1:50 Santa Cruz
Biotechnologies
(sc-20109)
Mouse anti-GATA4 1:50 Santa Cruz
Biotechnologies
(sc-25310)
Secondary
antibodies
Alexa Fluor 488 donkey
anti-goat IgG
1:2000 Thermo Fisher Scientiﬁc
(A-11055)
Alexa Fluor 488 donkey
anti-mouse IgG
1:2000 Thermo Fisher Scientiﬁc
(A-21202)
Alexa Fluor 488 donkey
anti-rabbit IgG
1:2000 Thermo Fisher Scientiﬁc
(A-21206)
Alexa Fluor 488 donkey
anti-mouse IgM
1:2000 Thermo Fisher Scientiﬁc
(A-21042)
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The expression of speciﬁc pluripotency and germ layer markers
were analysed using conventional ICC staining. Cells were ﬁxed in 4%
PFA (20 min, RT), permeabilized with 0.1% Triton X-100 (5 min, RT)
and blocked in 1% bovine serum albumin (1 h, RT). The cells were incu-
bated with primary antibodies (overnight at 4 °C) and visualized with
secondary antibodies. For nuclei counterstaining 0.2 μg/ml DAPI
(20 min, RT) was used. The antibodies and applied dilutions are listed
in Table 2. The cells were observed under ﬂuorescent microscope
equipped with 3D imaging module, (Axio Imager system with
ApoTome; Carl Zeiss) controlled by AxioVision 4.8.1 microscope soft-
ware (Carl Zeiss).
Alkaline phosphatase (AP) staining
For detecting Alkaline phosphatase activity the 4% PFA ﬁxed cells
(20 min, RT) were stained AP solution (29.7 mM TRIS base; 6 mMmaleic acid, pH 8.5–9.0; with 0.08% MgCl2, 10.8 mM Naphtol-As MX
Phosphate; 23 μM Fast Red TR Salt; all from Sigma Aldrich) for 30 min
(RT). Samples were observed with Axio Imager system (Carl Zeiss).
Karyotyping
Cells were treated with KaryoMAX® Colcemid™ Solution
(Thermo Fisher Scientiﬁc) and processed with standard methods.
Standard Giemsa-banded karyotype was performed by Istenhegyi
GeneDiagnostic Center, Budapest (Hungary) and a minimum of 20
metaphases were analysed. The chromosomes were classiﬁed accord-
ing to the International System for Human Cytogenetic Nomenclature
(ISCN).
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